Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$24.26 USD
+0.46 (1.93%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $24.26 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Myriad Genetics, Inc. [MYGN]
Reports for Purchase
Showing records 181 - 200 ( 243 total )
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Terminating Coverage Due to Analyst Departure.
Provider: COLLIERS SECURITIES
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: CMS Releases Preliminary Payment Methodology Continued Uncertainty for BRACAnalysis Reimbursement Until at Least November, Maintain NEUTRAL
Provider: COLLIERS SECURITIES
Analyst: HUSAIN J
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: CMS Releases Preliminary Payment Methodology Continued Uncertainty for BRACAnalysis Reimbursement Until at Least November, Maintain NEUTRAL
Provider: COLLIERS SECURITIES
Analyst: HUSAIN J